What Sanyou Bio does

Sanyou Biopharmaceuticals Co., Ltd. (operating as Sanyou Bio) is a Shanghai-based, privately held contract research organization founded in 2015 by Lang Guojun. The company provides antibody drug discovery and development services to multinational pharmaceutical firms, biotech innovators, research institutions, CDMOs, and CROs, operating an integrated services platform that spans 10 major functional modules and 50+ sub-platforms covering the path from target identification through PCC molecule, IND application, and clinical sample production.

The company's technology stack is built around three core platforms. AI-STAL (AI Super-Trillion Antibody Library) is an intelligent biologics discovery engine with a stated 10^13-scale antibody and peptide library, claimed to be 100 to 1,000 times larger than conventional libraries; its 2.0 release compresses candidate antibody discovery to a stated 14-day cycle via AI-guided digital panning and intelligent sequence-structure analysis. SAI-DA 1.0, launched in May 2026, integrates computational and laboratory capabilities for end-to-end AI-driven drug development. Clicklinks, also launched in May 2026, is an Innovation Hub with six core modules and nearly 70 standardized technology platforms covering monoclonal antibodies, bispecific antibodies, ADCs, and CAR-T therapies, and serves as a multi-stakeholder coordination portal.

Sanyou generates revenue through fee-for-service drug discovery work and collaborative development engagements, with 2,000+ clients served and 2,000+ projects completed over the past decade, including 10+ programs that have progressed to IND submission or Phase III clinical trials. The company operates more than 20,000 m2 of R&D and GMP facilities in Shanghai and runs global business centers across Asia, North America, and Europe. Sanyou achieved break-even in 2024 and sustained positive cash flow in 2025, and received Shanghai Municipal Enterprise Technology Center recognition alongside ISO 9001 and ISO 27001 dual certification in 2026. The company remains private, with disclosed investors including LH Ventures, Montesy Investment, Huatai Zijin, Liferiver Biotechnology, Shenzhen Yanghe Biomedicine Industry Investment (a Gree Group healthcare platform), and Zhijiang Biotech.

Name

Sanyou Bio

Legal name

Sanyou Biopharmaceuticals Co., Ltd.

Website

https://sanyoubio.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Sanyou Bio is a Shanghai-based, privately held CRO founded in 2015 that delivers AI-enabled antibody drug discovery and development services — including 14-day candidate discovery, co-development to IND, and clinical sample production — to 2,000+ global biopharma, biotech, research, and CDMO clients.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Health Services (8000)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Antibody drug discovery
• Contract research services
• Biologics R&D
• AI drug discovery
• Preclinical development

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Drug Discovery Services: Sanyou Bio provides one-stop comprehensive solutions covering the entire drug discovery value chain from target to PCC molecule, PCC molecule to IND application, and IND application to clinical sample production, through 10 major functional modules and 50+ sub-platforms.
2. Collaborative Drug Development: The company generates revenue through collaborative drug development projects with biopharmaceutical partners, with more than 10 projects entering clinical development stages including IND submissions and Phase III trials.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Sanyou Bio provides one-stop contract research and collaborative drug development services for innovative antibody drugs, organized around three proprietary AI-powered platforms: AI-STAL 2.0 (a 10^13-scale antibody library with AI-guided discovery), SAI-DA 1.0 (an AI-Drug Accelerator), and Clicklinks (an open innovation hub with ~70 standardized technology platforms). Services span target discovery, antibody generation, antibody engineering, drugability analysis, in vitro/in vivo functional assays, process development, quality control, and pilot-scale production, covering modalities from monoclonal and bispecific antibodies to ADCs and CAR-T therapies. The company serves pharmaceutical companies, biotech innovators, research institutions, CDMOs, and CROs globally.

Product overview

Sanyou Bio operates a platform-plus-modules architecture built around three core platforms: AI-STAL (AI Super-Trillion Antibody Library), SAI-DA (Sanyou AI-Drug Accelerator), and Clicklinks. AI-STAL serves as the intelligent biologics innovation engine with 10-trillion scale molecule libraries for antibody discovery; SAI-DA provides AI-driven computational and laboratory capabilities for end-to-end drug development; and Clicklinks functions as an open innovation hub connecting pharmaceutical ecosystem stakeholders. The integrated platform covers one-stop solutions from target to PCC molecule, PCC molecule to IND application, and IND application to clinical sample production, spanning 10 major functional modules and 50+ sub-platforms.

Differentiator

Problem solved

Functional benefit

Brands

• AI-STAL: AI Super-Trillion Antibody Library platform - an intelligent biologics innovation engine with AI-powered capabilities across target discovery, molecule generation, optimization, and evaluation. Platform capacity reached 10-trillion level (10^13).
• SAI-DA
• Clicklinks

Products and services

• AI-STAL 2.0 (AI Super-Trillion Antibody Library) AI-powered intelligent biologics innovation engine providing ultra-trillion-scale (10^13) antibody and peptide molecule libraries for target discovery, molecule generation, optimization, and evaluation; integrates AI-guided digital panning and intelligent sequence-structure analysis. Used by biopharmaceutical partners to compress antibody candidate discovery from library panning to core molecule validation in 14 days.
• SAI-DA 1.0 (Sanyou AI-Drug Accelerator) AI-driven drug development platform integrating advanced computational and laboratory capabilities to accelerate end-to-end drug discovery and development. Built to support Sanyou Bio's integrated R&D service offering from target identification through clinical sample production for biopharmaceutical partners.
• Clicklinks (Innovation Hub for Original Drug Discovery) One-stop online innovation hub portal that connects stakeholders across the drug development value chain, providing access to six core modules and nearly 70 standardized technology platforms covering monoclonal antibodies, bispecific antibodies, ADCs, and CAR-T modalities. Used by biotech innovators, pharmaceutical companies, research institutions, CDMOs, CROs, and investors to identify partners, technologies, and resources.
• One-Stop Antibody Drug Discovery & Development Services Comprehensive contract research service covering the entire drug discovery value chain from target to PCC molecule, PCC molecule to IND application, and IND application to clinical sample production, through 10 major functional modules and 50+ sub-platforms. Used by pharmaceutical companies, biotech innovators, CDMOs, CROs, and research institutions globally.
• Collaborative Drug Development Programs Collaborative drug development engagements with biopharmaceutical partners covering co-discovery and co-development of antibody drug candidates. The company has more than 10 collaborative projects that have advanced to clinical development stages, including IND submissions and Phase III trials.

Quantifiable outcome

• 10-trillion scale (10^13) antibody library capacity
• +5 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Partnerships

Two partnerships are on record, tiered major.

• TongxieyimajorStrategic or Co-development Partner · 8 February 2026Co-hosted the 2026 China New Drug Source Innovation Forum in Shanghai, bringing together academic, industry, and investment leaders to discuss breakthrough pathways for source innovation in new drug development.
• Clicklinks Strategic Partners (14 agreements)majorStrategic or Co-development Partner · 8 February 2026Fourteen strategic partnership agreements were signed during the launch of the Clicklinks Original Innovative Drug Innovation Hub, covering collaborations with biotech innovators, pharmaceutical companies, research institutions, CDMOs, CROs, and investors.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Adimab: US-based antibody discovery platform offering proprietary yeast-based library screening and protein engineering services to pharma and biotech. Closely comparable as a pure-play antibody discovery CRO with platform IP and partnership-based economics.
• AbCellera Biologics: Canadian AI-driven antibody discovery platform operating a high-throughput antibody screening engine and partnering with pharma on therapeutic antibody programs. Highly comparable as a tech-forward CRO monetizing proprietary discovery infrastructure to global biopharma.
• BigHat Biosciences: US-based AI-driven antibody design company combining machine learning with high-throughput wet-lab validation to engineer therapeutic antibodies. Comparable as an AI-native antibody engineering CRO competing for similar biopharma partnerships at earlier stage.
• Ablexis / AlivaMab Discovery Services: US-based antibody discovery service provider using the AlivaMab Mouse platform for therapeutic antibody generation. Comparable as a specialized antibody discovery CRO serving pharma partnerships with proprietary transgenic platforms.

Broad incumbents

• GenScript ProBio: Biologics CDMO arm of GenScript providing antibody discovery, cell line development, and manufacturing services globally. Comparable as a Chinese-headquartered biologics service platform with overlapping antibody discovery capabilities and similar multinational customer base.
• WuXi Biologics: China-headquartered global biologics CRO/CDMO offering end-to-end discovery, development, and manufacturing services including antibody platforms. Comparable as a scaled Chinese biologics service provider serving multinational pharma, but with much broader scope (CMC, manufacturing) beyond discovery.
• Pharmaron: China-headquartered global CRO/CDMO providing integrated drug discovery, preclinical, and CMC services including biologics. Comparable as a Chinese CRO with biologics discovery capabilities serving multinational pharma, but operates at much broader scale across modalities.
• Charles River Laboratories: Global CRO offering discovery, safety assessment, and manufacturing services including biologics and antibody discovery through its Distributed Bio and other acquired platforms. Comparable as a large incumbent CRO with antibody discovery offerings and global pharma customer overlap.

Emerging players

• Generate Biomedicines: US-based generative AI biologics platform creating novel protein therapeutics computationally. Comparable as an AI-first biologics platform targeting antibody and protein drug discovery, but more therapeutics-internal vs. pure-CRO orientation.

Regional players

• Hangzhou Tigermed: Leading China-based clinical CRO providing clinical trial and biopharmaceutical R&D services. Comparable as a Chinese-headquartered CRO serving biopharma, though more clinical-stage focused versus Sanyou's discovery-stage specialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanyou Bio